Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Adefovir · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Adefovir | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Other antiretroviral therapy IF on a stable dose for at least 4 weeks prior to study entry. * Prophylactic therapy with aerosolized pentamidine, oral trimethoprim/sulfamethoxazole (Bactrim, Septra) or dapsone, and fluconazole or ketoconazole IF...
Top 20 of 28 competitors
Adefovir is an investigational small molecule being studied for the treatment of HIV Infections. It is in Phase 1 clinical development and has not been approved by the FDA. The drug is being developed by Gilead Sciences, Inc. (GILD).
Adefovir is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker GILD. The drug is currently in Phase 1 clinical trials for HIV Infections.
Adefovir is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total of 40 participants enrolled. The drug remains investigational and has not received FDA approval.
Adefovir has been studied in two completed Phase 1 trials. NCT00002115 evaluated the safety, tolerance, and pharmacokinetics of Adefovir in patients with advanced HIV disease. NCT00002326 studied the safety and effectiveness of zidovudine plus Adefovir in HIV-infected patients.
Adefovir is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for HIV Infections. All completed trials are early-stage safety and dosing studies, and the drug has not progressed to later-stage efficacy trials.